Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR” All of Pacira’s Director Nominees
Pacira BioSciences said Glass Lewis recommended shareholders vote “FOR” all three of its director nominees—Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans—and “AGAINST” the three nominees proposed by DOMA Perpetual Capital Management on the BLUE proxy card ahead of the June 9, 2026 annual meeting. Glass Lewis cited Pacira’s 37% one-year total shareholder return in 2025 and 23.8% cumulative since its 5x30 strategy launch.
How this was made
The 30-second read
Why it matters
Glass Lewis’ FOR/AGAINST recommendation strengthens Pacira’s case for continued pursuit of its 5x30 strategy and incumbent leadership, potentially lowering near-term uncertainty for shareholders considering governance-driven risk.
Market read
This is a governance catalyst for PCRX into the annual meeting, with an independent proxy advisory endorsement for the incumbent slate.
What to watch
Actual voting outcomes, dissident campaign momentum, and any subsequent filings/settlement talks could dominate price action more than the advisory recommendation.
Background
Pacira is facing a proxy contest ahead of its June 9, 2026 annual meeting, with DOMA Perpetual Capital Management pushing competing director nominees on a BLUE vs white proxy card basis.
Ticker impact
Glass Lewis recommends Pacira shareholders vote FOR all three director nominees and AGAINST DOMA’s slate ahead of the June 9, 2026 annual meeting.
Near-term bias toward stability/less downside volatility into the June 9 vote; magnitude likely modest absent new financial/drug catalysts.
The article is a time-sensitive corporate governance catalyst (proxy contest) with a clear recommendation, but it does not introduce new earnings, trial results, or deal terms.
Market effects
Could modestly influence sentiment around governance risk in specialty pharma/biopharma proxy contests, but no direct sector fundamentals change.
Primarily US-listed small/mid-cap sentiment; limited broader regional spillover expected.
Mostly local to Pacira’s shareholder base and proxy contest; limited global relevance.
Counterpoint
A favorable proxy-advisor stance may not fully deter dissident pressure if investors prioritize valuation or strategic alternatives over board process.
Key entities
- public_companyPacira BioSciences, Inc.
Subject of the proxy contest; incumbent board seeks reelection and continued execution of the 5x30 strategy.
- proxy_advisory_firmGlass Lewis & Co., LLC
Independent proxy advisory firm issuing the FOR/AGAINST recommendation on the BLUE proxy card.
- activist_investorDOMA Perpetual Capital Management LLC
Dissident proposing an alternative slate of director nominees and claims regarding Pacira’s strategy/board.
